Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2021

View Archived Issues

Neuron-specific delivery platform based on a chimeric toxin for botulism postexposure treatment

Incyte initiates phase I/II study of INCB-000928 in patients with anemia due to MF

Phase I trial investigates NNC0361-0041 for type 1 diabetes

Study links ALS gene to tumor suppressor, transcription changes

Membrane rupture is active event

Xarelto approved in Japan to treat children with VTE and to prevent VTE recurrence

Exelixis initiates first-in-human study of XL-102 in advanced or metastatic solid tumors

Bavencio approved in Europe as first-line maintenance for urothelial carcinoma

UCB patents dopamine D1 receptor PAMs

Roche synthesizes MGL inhibitors

Progen presents new fusion proteins for autoimmune diseases

Chinese researchers present CAR T-cell therapy for cancer

AR agonist-based strategy proposed for ER+ breast cancer

Zymso approved in Japan for interstitial cystitis

Merck & Co. discontinues development of V-590 and V-591 vaccine candidates

New NFE2L2 activators patented by Senju Pharmaceutical

Dosing begins in phase II study of MVC-COV-1901 vaccine in Taiwan

StemVacs induces regression of glioma, lung and colorectal cancer tumors in vivo

Ivermectin use tied to lower mortality in patients with COVID-19

5-HT2B as a novel therapeutic target to improve microstructural remodeling post-MI

Dosing begins in phase I study of TJ-210 in advanced solid tumors

Rinvoq approved in E.U. for psoriatic arthritis and ankylosing spondylitis

Curadigm's Nanoprimer-based project selected for Sanofi iTech Awards program

One-year data from SPIRIT Extension study of relugolix combination therapy in endometriosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...